Blue Wave Therapeutics is a pioneering biotech company focused on developing targeted radionuclide therapies for the treatment of solid tumors. Our proprietary radioactive biopolymer platform leverages targeted alginate nanoparticles to deliver radionuclide payloads directly to tumor cells, ensuring minimal damage to healthy tissues. We are dedicated to addressing the unmet medical needs of cancer patients worldwide.

Our mission is to transform the landscape of cancer treatment by providing innovative, effective, and targeted radionuclide therapies. We aim to improve survival rates and quality of life for patients with challenging and underserved tumors, such as glioblastoma. Through our cutting-edge research and development, we strive to bring new hope to those battling cancer.

At Blue Wave Therapeutics, we envision a future where targeted radionuclide therapies become the standard of care for a variety of solid tumors. We are committed to advancing our technology to treat not only glioblastoma but also other aggressive cancers with limited treatment options. Our goal is to make a significant impact on global health by extending and enhancing the lives of cancer patients.